Author:
Van Gorp T,Cadron I,Despierre E,Daemen A,Leunen K,Amant F,Timmerman D,De Moor B,Vergote I
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. HE4 EIA product insert, version 2008-09. Available from URL: http://www.fdi.com/documents/products/inserts/eia/HE4%20EIA%20404-10,%202008-09,%20r1.pdf (accessed 1 April 2010)
2. Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P, Urban N (2010) Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 116: 378–383
3. Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski Jr VR, Knapp RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883–887
4. Bingle L, Singleton V, Bingle CD (2002) The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 21: 2768–2773
5. Bon GG, Kenemans P, Verstraeten R, van Kamp GJ, Hilgers J (1996) Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 174: 107–114
Cited by
268 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献